MORGAN STANLEY PLC/CALL/AMGEN/360/0.1/20.09.24 | Delayed Börse Stuttgart 03:58:27 2024-06-13 EDT | ||
| 0.18 EUR | -3.23% |
|
| Current month | -25.60% | ||
| 1 month | -43.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 0.18 | -3.23% |
| 24-06-12 | 0.186 | -4.62% |
| 24-06-11 | 0.195 | -3.94% |
| 24-06-10 | 0.203 | -11.74% |
| 24-06-07 | 0.23 | -4.17% |
Delayed Quote Börse Stuttgart
Last update June 13, 2024 at 03:58 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB0BQJ |
| ISIN | DE000MB0BQJ7 |
| Date issued | 2022-11-09 |
| Strike | 360 $ |
| Maturity | 2024-09-20 (99 Days) |
| Parity | 10 : 1 |
| Emission price | 1.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.28 € |
|---|---|
| Lowest since issue | 0.101 € |
| Spread | 0.038 € |
| Spread % | 18.18% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
301.1
USD
Average target price
316.3
USD
Spread / Average Target
+5.05%
- Stock Market
- Warrants
- Warrant
